Galectin Therapeutics CMO Buys Shares Below Market as Belapectin Data Sparks Insider Confidence

Insider Buying Sparks Optimism for Galectin Therapeutics

On May 26 2026, Chief Medical Officer Jamil Khurram executed a Rule 10b5‑1 purchase of 568 shares of Galectin Therapeutics at $1.23 per share, a price that was 0.1 % below the market level of $2.70. The move, part of a pre‑planned plan adopted in February, signals confidence from a senior executive who is intimately involved in the company’s drug‑development pipeline. The trade arrives just after a highly positive buzz around the company’s belapectin data at the European Association for the Study of the Liver, which has already sparked a 7 % weekly rise and a 16 % monthly gain in the share price.

What Does the Buy Mean for Investors?

Insider buying is often interpreted as a sign that executives believe the market is undervaluing the company. Khurram’s purchase is modest—less than 0.1 % of the outstanding shares—but it is consistent with a broader trend of recent insider activity. In the past year, several executives, including CEO Joel Lewis and CFO Jack Callicut, have taken sizeable option and stock purchases. Combined with the company’s recent trial successes, this pattern suggests that insiders see a clear upside to the belapectin platform and the broader galectin‑targeted portfolio.

For the investor, the trade should be viewed as a confirmation that the company’s strategic direction is resonating with key decision‑makers. It also highlights the potential for a rebound in valuation as the company continues to navigate regulatory milestones and expands its pipeline. A modest 7 % weekly gain in a company with a market cap of $183 million is encouraging, especially given the negative trailing P/E of –6.74, indicating that earnings are still in development but could turn positive as the product candidates mature.

Khurram’s Transaction History: A Pattern of Gradual Accumulation

Khurram’s insider activity over the last 18 months shows a steady, incremental build‑up of equity. Early in 2026 he executed large option purchases (65,000 options) and a 100,000‑share restricted stock unit grant, followed by a series of common‑stock purchases and sales in December 2025. In that month he bought 6,463 shares at $2.20, 8,500 at $2.50, and sold 4,479, 6,463, and 8,500 shares at $7.04—a clear exercise of vested options at the same strike. The current purchase at $1.23 represents the first time he has bought shares below the current market level, suggesting a belief in future upside rather than a hedge against dilution.

This pattern—large option grants, periodic exercise, and opportunistic purchases when the price dips—indicates that Khurram is positioning himself for long‑term gains tied to the success of the company’s therapeutic programs. It also shows a willingness to commit capital while the share price remains volatile, reinforcing the notion that the CMO is confident in the company’s trajectory.

Implications for the Company’s Future

The timing of Khurram’s buy aligns with the recent belapectin data, which could accelerate regulatory review and commercialization plans. If the company can translate these findings into clinical benefits and secure approvals, the value of the stock could rise sharply, rewarding early insiders and creating a positive feedback loop of further investments. Conversely, the company’s negative earnings and reliance on external financing mean that any setback could dampen momentum. Investors should monitor upcoming data releases, partnership announcements, and any changes in the company’s capital structure, as these factors will heavily influence the stock’s performance.

Bottom Line

Jamil Khurram’s latest Rule 10b5‑1 purchase, though small in scale, is a meaningful endorsement from a senior executive at a critical juncture. It reflects a broader pattern of insider confidence, dovetails with positive clinical data, and provides a modest boost to a stock that has already shown strong weekly and monthly gains. For investors, the trade is a signal to stay attentive to the company’s clinical milestones and capital‑raising activities—key drivers that will ultimately determine whether Galectin Therapeutics can translate its galectin technology into profitable therapies.